A strip of paper can now indicate presence of pathogens, tumor DNA, or any genetic signature of interest. 100-fold greater sensitivity, the ability to detect multiple targets at once, and other new features further enhance SHERLOCK’s power for detecting genetic signatures.
The team that first unveiled the rapid, inexpensive, highly sensitive CRISPR-based diagnostic tool called SHERLOCK has greatly enhanced the tool’s power, and has developed a miniature paper test that allows results to be seen with the naked eye — without the need for expensive equipment.
The SHERLOCK team developed a simple paper strip to display test results for a single genetic signature, borrowing from the visual cues common in pregnancy tests. After dipping the paper strip into a processed sample, a line appears, indicating whether the target molecule was detected or not.
This new feature helps pave the way for field use, such as during an outbreak. The team has also increased the sensitivity of SHERLOCK and added the capacity to accurately quantify the amount of target in a sample and test for multiple targets at once. All together, these advancements accelerate SHERLOCK’s ability to quickly and precisely detect genetic signatures — including pathogens and tumor DNA — in samples.
Described today in Science, the innovations build on the team’s earlier version of SHERLOCK (shorthand for Specific High-sensitivity Enzymatic Reporter unLOCKing) and add to a growing field of research that harnesses CRISPR systems for uses beyond gene editing. The work, led by researchers from the Broad Institute of MIT and Harvard and the Massachusetts Institute of Technology, has the potential for a transformative effect on research and global public health.
“SHERLOCK provides an inexpensive, easy-to-use, and sensitive diagnostic method for detecting nucleic acid material — and that can mean a virus, tumor DNA, and many other targets,” said senior author Feng Zhang, core institute member at the Broad Institute, investigator at the McGovern Institute for Brain Research at MIT, and the Patricia and James Poitras ’63 Professor in Neuroscience at MIT. “The SHERLOCK improvements now give us even more diagnostic information and put us closer to a tool that can be deployed in real-world applications.”
The researchers previously showcased SHERLOCK’s utility for a range of applications. In the new study, the team uses SHERLOCK to detect cell-free tumor DNA in blood samples from lung cancer patients and to detect synthetic Zika and Dengue virus simultaneously, in addition to other demonstrations.
Clear results on a paper strip
“The new paper readout for SHERLOCK lets you see whether your target was present in the sample, without instrumentation,” said co-first author Jonathan Gootenberg, a Harvard graduate student in Zhang’s lab as well as the lab of Broad core institute member Aviv Regev. “This moves us much closer to a field-ready diagnostic.”
The team envisions a wide range of uses for SHERLOCK, thanks to its versatility in nucleic acid target detection. “The technology demonstrates potential for many healthcare applications, including diagnosing infections in patients and detecting mutations that confer drug resistance or cause cancer, but it can also be used for industrial and agricultural applications where monitoring steps along the supply chain can reduce waste and improve safety,” added Zhang.
At the core of SHERLOCK’s success is a CRISPR-associated protein called Cas13, which can be programmed to bind to a specific piece of RNA. Cas13’s target can be any genetic sequence, including viral genomes, genes that confer antibiotic resistance in bacteria, or mutations that cause cancer. In certain circumstances, once Cas13 locates and cuts its specified target, the enzyme goes into overdrive, indiscriminately cutting other RNA nearby. To create SHERLOCK, the team harnessed this “off-target” activity and turned it to their advantage, engineering the system to be compatible with both DNA and RNA.
SHERLOCK’s diagnostic potential relies on additional strands of synthetic RNA that are used to create a signal after being cleaved. Cas13 will chop up this RNA after it hits its original target, releasing the signaling molecule, which results in a readout that indicates the presence or absence of the target.
Detecting multiple targets
The SHERLOCK platform can now be adapted to test for multiple targets. SHERLOCK initially could only detect one nucleic acid sequence at a time, but now one analysis can give fluorescent signals for up to four different targets at once — meaning less sample is required to run through diagnostic panels. For example, the new version of SHERLOCK can determine in a single reaction whether a sample contains Zika or dengue virus particles, which both cause similar symptoms in patients. The platform uses Cas13 and Cas12a (previously known as Cpf1) enzymes from different species of bacteria to generate the additional signals.
SHERLOCK’s second iteration also uses an additional CRISPR-associated enzyme to amplify its detection signal, making the tool more sensitive than its predecessor. “With the original SHERLOCK, we were detecting a single molecule in a microliter, but now we can achieve 100-fold greater sensitivity,” explained co-first author Omar Abudayyeh, an MIT graduate student in Zhang’s lab at Broad. “That’s especially important for applications like detecting cell-free tumor DNA in blood samples, where the concentration of your target might be extremely low. This next generation of features help make SHERLOCK a more precise system.”
The authors have made their reagents available to the academic community through Addgene and their software tools can be accessed via the Zhang lab website and GitHub.
The Latest on: Disease detection
via Google News
The Latest on: Disease detection
- 7,000 challenges: The basis and burden of rare diseaseson February 23, 2021 at 9:21 am
Around 7,000 rare diseases have been identified, impacting an estimated 300 million people around the world, about 4% of the global population. Approximately 50% of those diagnosed with a rare disease ...
- BRIC Diagnostic Imaging Equipment Market Growing at a CAGR of 9.2% - Rising Awareness on Early Disease Detectionon February 22, 2021 at 3:36 pm
The BRIC diagnostic imaging equipment market is projected to reach USD 8.3 billion by 2024 from USD 5.3 billion in 2019, at a CAGR of 9.2% during the forecast period ...
- Grape disease detection from the final frontieron February 22, 2021 at 7:20 am
Cornell’s Katie Gold is using the technology to study grape pathogens in New York state. (Courtesy NASA/Cornell University) Pathologist Katie Gold joined Cornell University last year to perform ...
- A different strategy for wastewater detection of SARS-CoV-2on February 21, 2021 at 6:31 pm
Researchers tested a variety of RNA concentration and extraction methods and assays to develop a protocol for testing SARS-CoV-2 in wastewater, which may help improve COVID-19 surveillance.
- Novel Multicancer Early Detection Technology––Potential Value to Employers and the Workforceon February 19, 2021 at 7:09 am
Multicancer early detection technology could help reduce cancer mortality compared to the current strategy of single-cancer screening tests.
- Disease detection device could rival accuracy of canine noseon February 19, 2021 at 4:07 am
Researchers have reportedly developed a device with greater sensitivity than a dog’s nose, aiming for more accurate disease detection in lab samples.
- A Disease-Sniffing Device That Rivals a Dog's Noseon February 18, 2021 at 7:22 pm
Trained dogs can detect cancer and other diseases through smell. Now, a miniaturized detector can analyze trace molecules to mimic the process ...
- Toward a disease-sniffing device that rivals a dog’s noseon February 18, 2021 at 7:58 am
Numerous studies have shown that trained dogs can detect many kinds of disease — including lung, breast, ovarian, bladder, and prostate cancers, and ...
- Study confirms cell-free DNA in urine as potential method for cancer detectionon February 18, 2021 at 7:17 am
Urinalysis has long been a staple of physical exams to detect and manage a number of diseases and disorders, but not cancer. What if it were that easy, though, and cancer was detected in its very ...
via Bing News